
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is positioned to be a leader in the multi-cancer early detection market with its innovative and comprehensive Galleri blood test, which has demonstrated strong growth in sales and test volume. The upcoming ASCO presentation and potential FDA approval and Medicare reimbursement will be key upcoming catalysts for the company's success. However, there are potential risks, including FDA approval delays or limitations, lack of Medicare reimbursement, and a slowdown in the self-pay market. Further risks to the medical and life science tools sector as a whole, such as reduced research and development budgets and government funding, may also impact GRAIL's success.
Bears say
GRAIL is currently facing challenges such as continued discounting and lower financial forecasts, and there is a significant downside risk if FDA approval for their Galleri test is not granted or Medicare does not provide coverage. However, there is also potential for positive catalysts, such as a positive ASCO data presentation and FDA approval, which could support the company's favorable view on the multi-cancer early detection (MCED) opportunity. Despite an attractive risk/reward profile, the impact of these challenges on the stock's performance outweighs the potential positive catalysts, leading to a negative outlook for GRAIL's stock performance.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares